SEC Filing Summary: Aadi Bioscience, Inc. (AADI)
Business Context and Reporting Period
This Form 8-K was filed by Aadi Bioscience, Inc. on August 7, 2024. The filing serves to announce the company's financial results for the quarter ended June 30, 2024. The registrant is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol AADI.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were released in a press release (Exhibit 99.1) but does not contain the data itself within the provided text.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this Form 8-K. The filing references an attached press release for the full details of the quarterly results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and Item 9.01, including the attached press release, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are enumerated in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 7, 2024) for actual financial figures.
- Verify the specific revenue and net loss figures for the quarter ended June 30, 2024.
- Check the cash balance and burn rate disclosed in the full press release.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the press release.